Company Overview - Pfizer Inc. has entered into a definitive agreement to acquire Metsera, a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases [1][2] - The acquisition is expected to enhance Pfizer's portfolio with differentiated oral and injectable therapies that have potential best-in-class efficacy and safety profiles [1][2] Acquisition Details - Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion [3] - The agreement includes a contingent value right (CVR) that could provide additional payments of up to $22.50 per share based on specific clinical and regulatory milestones [3] Metsera's Portfolio - Metsera has four programs in clinical development, including MET-097i and MET-233i, both of which are injectable GLP-1 receptor agonists [2][4] - The company is also advancing oral GLP-1 RA candidates and additional preclinical hormone therapeutics aimed at addressing unmet needs in obesity treatment [2][4] Strategic Importance - The acquisition aligns with Pfizer's strategy to invest in impactful opportunities within the growing obesity treatment market, which is associated with over 200 health conditions [2] - Pfizer aims to leverage its manufacturing and commercial infrastructure to accelerate the development of Metsera's promising therapeutic candidates [2][5]

Group 1 - Pfizer is planning to acquire weight loss drug developer Metsera for up to $7.3 billion, with an initial cash offer of $47.50 per share, representing a 42.5% premium over Metsera's last closing price of $33.32 [1][5] - The acquisition comes after Pfizer faced setbacks in its own weight loss drug development, particularly with the experimental drug danuglipron, which was abandoned due to poor tolerance and safety concerns [5][6] - Metsera, founded in 2022, is developing obesity treatments based on GLP-1 mechanisms and other biological targets, with its lead candidate MET-097i showing an average weight loss of 11.3% in mid-stage trials [5][6] Group 2 - The global weight loss drug market is projected to reach $150 billion by the early 2030s, indicating strong investor interest in next-generation weight loss therapies [3][6] - Competitors like Eli Lilly and Novo Nordisk are intensifying their dominance in the GLP-1 weight loss drug sector, creating high barriers for new entrants [6] - By acquiring Metsera, Pfizer aims to quickly gain access to an established drug pipeline and clinical data, avoiding the lengthy development process from scratch [6]

（文章来源：第一财经） Metsera美股盘前涨幅扩大至50%，此前有报道称，辉瑞接近以73亿美元收购该公司。 ...

Core Insights - Pfizer is nearing a $7.3 billion acquisition of weight-loss company Metsera, with an initial cash offer of $47.50 per share, potentially increasing to $73 billion based on performance milestones, representing a 110% premium over Metsera's last closing price of $33.32 [1] Company Summary - Metsera's stock surged by approximately 50% in pre-market trading, reflecting investor optimism regarding the acquisition [1] - The acquisition will provide Pfizer access to Metsera's weight-loss injection MET-233i, which has shown promising results in early trials, enabling patients to lose up to 8.4% of their weight in 36 days [1] - MET-233i may offer a competitive advantage over existing products from market leaders like Novo Nordisk and Eli Lilly by reducing the frequency of administration from weekly to monthly [1] Market Context - The weight-loss drug market is valued in the billions, indicating significant growth potential for Pfizer post-acquisition [1] - Metsera's market capitalization was reported at $3.5 billion prior to the acquisition announcement, highlighting the substantial premium Pfizer is willing to pay [1]

Group 1 - Pfizer (PFE.US) is reportedly close to acquiring weight loss drug company Metsera for $7.3 billion, with an initial cash payment of $47.50 per share and potential milestone payments of $22.50 per share, bringing the total valuation to $7.3 billion [1] - The acquisition offer represents a premium of approximately 110% over Metsera's closing price of $33.32 last Friday [1] Group 2 - As of September 19, Pfizer's stock closed at $24.030, with a pre-market price of $24.420, reflecting a 1.62% increase [1] - Pfizer's total market capitalization is approximately $136.62 billion, with a price-to-earnings ratio of 12.71 and a dividend yield of 7.07% [1]

Group 1: Acquisition Details - Pfizer Inc. is nearing a $7.3 billion acquisition of Metsera Inc., a biotech firm focused on obesity treatments, with a cash offer of $47.50 per share and an additional $22.50 per share based on performance milestones [1] - The acquisition is part of Pfizer's strategy to re-enter the obesity drug market after previously discontinuing its own candidate due to safety concerns [3] Group 2: Metsera's Product and Market Position - Metsera, founded in 2022, is developing injectable and oral hormone analog peptides for obesity treatment, with its lead candidate, MET-097i, showing an average weight loss of 11.3% in mid-stage trials [2] - The drug's once-monthly dosing schedule may provide a competitive advantage over existing weekly GLP-1 injections [2] Group 3: Market Context and Future Outlook - The global demand for weight-loss therapies is projected to reach $150 billion by the early 2030s, positioning Pfizer to compete with major players like Eli Lilly and Novo Nordisk [3] - The deal highlights the increasing reliance of big pharma on biotech innovation to stay competitive in high-growth therapeutic areas [4]

智通财经APP获悉，据报道，辉瑞(PFE.US)即将以73亿美元收购减肥药初创公司Metsera(MTSR.US)，此 举旨在其备受关注的减肥药项目近期受挫后强化产品线布局。据知情人士透露，该交易最早可能于周一 正式宣布。辉瑞将以每股47.50美元现金收购Metsera，若达成特定业绩里程碑，还将额外支付每股22.50 美元，这一报价较Metsera上周五33.32美元的收盘价显著溢价。截至非工作时间，双方暂未对此置评。 作为新一代减肥药物领域的潜力企业之一，Metsera正参与争夺规模达数十亿美元的减肥药市场。收购 完成后，辉瑞将获得Metsera的减肥针剂MET-233i——在早期小型试验中，该药物帮助患者在36天内减 重最多达8.4%。 值得关注的是，与诺和诺德(NVO.US)、礼来(LLY.US)等市场龙头的现有产品相比，MET-233i可能实现 更低频次给药，使患者从每周注射一次减少至每月一次，可能与现有疗法形成差异。 据悉，辉瑞计划今年完成两至三笔总规模达150亿美元的交易以补充产品线，其自有减肥药业务此前被 视为进军该市场的核心突破口，但其减肥药丸项目的失败加大了首席执行官阿尔伯特·布尔拉的压力 ...

Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial Times reported on Monday. ...

Mergers and Acquisitions - Pfizer is nearing a potential $73 亿 (billion) 美元的收购，目标是肥胖症初创公司 Metsera [1]

Group 1 - Pfizer is nearing a potential acquisition of Metsera, a developer of anti-obesity drugs, valued at $7.3 billion [1] - The information regarding the acquisition was reported by the Financial Times, citing unidentified sources [1] Group 2 - The acquisition reflects Pfizer's strategic interest in expanding its portfolio in the anti-obesity drug market [1] - Metsera's development focus aligns with the growing demand for obesity treatments, indicating a significant market opportunity [1]